Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 20, 2010

View Archived Issues

Cancer vaccine CDX-1401 safe and active in ongoing phase I/II trial

Snapshots: Studies of new antibiotic CB-182804

Neurocrine Biosciences advances NBI-98854 into phase II testing

Aastrom obtains FDA fast track status for phase III CLI program

HIV vaccine ALVAC vCP1521 is safe in infants given birth to by HIV-infected women

DepoVax-based vaccination leads to tumor regression in vivo

Helix BioPharma files IND for phase II/III trial of IFN-alpha-2b for low-grade cervical lesions

Baraclude approved as therapy for chronic hepatitis B in adults with decompensated liver disease

Bharat Biotech launches H1N1 flu vaccine HNVAC in India

European orphan drug status for recombinant porcine factor VIII in hemophilia A

DiaMedica reports final data from DM-99 study in type 1 diabetes

Prolong Pharma secures funds to support programs in anemia

EMA recommends approval of CTI's pediatric investigation plan for Pixuvri

Sepracor changes name to Sunovion Pharmaceuticals

Two doses of Duromist oral spray show bioequivalence to Viagra tablet

New phosphodiesterase 7/8 inhibitors identified at sanofi-aventis

NeurogesX to submit sNDA to FDA for Qutenza patch in HIV-associated neuropathy

FDA grants fast track status for HPN-100 in urea cycle disorders

Vertex initiates phase IIa trial of VX-770/VX-809 for cystic fibrosis

Pathway Therapeutics presents new inhibitors of PI3K isoforms

Abbott describes novel GSK-3 beta inhibitors

Merck & Co. claims new diacylglycerol O-acyltransferase 1 inhibitors

New selective alpha2C-adrenoceptor agonists identified

Ocrelizumab reduces disease activity in phase II trial in relapsing-remitting MS

EC grants orphan drug status for S*BIO's SB-1518 in myelofibrosis

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026